TNDMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
TANDEM DIABETES CARE INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$16.38+0.14 (+0.86%)
Close on Oct 19, 2026
- Market cap
- $1.13B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
53.8%+1.6 pts over 5 years
Operating margin
-18.5%−16.9 pts over 5 years
Net margin
-20.2%−13.3 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +7.9% | +8.2% | +15.3% | +30.1% | |
| Gross profit | +11.5% | +9.8% | +16.0% | +35.3% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -290.0% | -12.3% | -97.9% | |
| Return on assets | -70.4% | -6.6% | -22.1% | |
| Current ratio | 2.93 | 6.14 | 2.55 | |
| Debt to equity | -13.32 | – | 2.00 | |
| Net debt to EBITDA | -0.44× | – | -1.29× | |
| Interest coverage | – | – | -23.7× | |
| Inventory turnover | 3.1× | 4.2× | 3.4× | |
| Capex to revenue | 10.6% | 5.5% | 2.0% | |
| Diluted shares | 3M | 61M | 67M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Tandem Diabetes Care generated $227.58M from operations and spent $144.26M on capital expenditure, dividends and share buybacks. 79% of that went back into the business.
Generated
$227.58M
Used
$144.26M
Capital expenditure$114.26M79%Dividends$00%Share buybacks$30.00M21%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-20.2%
×Asset turnover1.10×
×Equity multiplier4.42×
=Return on equity, FY2025-97.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -20.2% | 1.10× | 4.42× | -97.9% |
| FY2024 | -10.2% | 0.98× | 3.33× | -33.3% |
| FY2023 | -29.8% | 0.75× | 2.66× | -59.1% |
| FY2022 | -11.8% | 0.82× | 2.24× | -21.7% |
| FY2021 | 2.2% | 0.87× | 2.03× | 3.9% |
| FY2020 | -6.9% | 0.96× | 1.86× | -12.3% |
| FY2019 | -6.8% | 1.36× | 1.63× | -15.2% |
| FY2018 | -66.7% | 1.22× | 2.95× | -240.1% |
| FY2017 | -67.9% | 1.04× | -5.92× | 416.4% |
| FY2016 | -99.0% | 0.71× | 4.12× | -290.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$204.71M
- Cash generatingOperating cash flow above zero-$9.72M
- Return on assets improvedROA up on the prior year-10.1% → -21.2%
- Earnings backed by cashOperating cash flow above net income-$9.72M vs -$204.71M
- Less leverageLong-term debt to assets fell31.9% → 35.2%
- Better liquidityCurrent ratio rose2.93 → 2.55
- No dilutionShare count did not rise65M → 67M
- Gross margin improvedGross margin up on the prior year52.07% → 53.81%
- More efficientAsset turnover rose0.99 → 1.05